

Targeting a Modifiable Risk Factor: A Causal Framework Informs Strategies to Reduce Pressure Injuries

>>> Alderden J¹, Krikov S^{2,3}, Li H⁴, Johnny J^{3,5}, Vanderpuye-Orgle J², Gregg M², Wilson A^{2,3}
1. Boise State University, Boise, ID, USA, 2. Parexel International, Lexington, MA, USA, 3. University of Utah, Salt Lake City, UT, USA, 4. University of California, Berkeley, CA, USA, 5. Huntsman Cancer Institute, Salt Lake City, UT, USA

Background


- Pressure injuries (PrIs) are a serious complication in critically ill patients, with low serum albumin frequently being identified as a risk factor.
 - Despite the abundant literature on the association of hypoalbuminemia with PrI formation, a causal relationship remains a critical gap.
 - Identifying if hypoalbuminemia is causal is critical as it is a modifiable risk factor.
- The Roadmap for Causal Inference is a systematic process that guides researchers from formulating a well-stated research question to specifying a causal model, intervening on it to generate counterfactuals, linking it to observed data, estimating causal effects, and finally interpreting the results. It provides a structured approach for addressing causal questions while considering uncertainties and statistical modeling [1].

Methods

- The goal of the project was to estimate the interventional effect of serum albumin on pressure injury development using (non-interventional) observational data
- The data comes from the MIMIC IV dataset, capturing hospital admissions from 2008 to 2019 for almost 300,000 patients [2].
- We applied the steps of the roadmap for causal inference to estimate the protective effect of increased albumin against developing PrIs.
- Collaborative targeted maximum likelihood estimation (C-TMLE) [3] was used to estimate the Average Treatment Effect (ATE) of albumin on the development of PrIs.
- In addition, we estimated heterogeneous treatment effects, i.e., were there certain patients who would or wouldn't benefit from *exogenous* (externally-introduced) albumin.

REFERENCES

1. Dang and Balzer (2023). Start with the Target Trial Protocol, Then Follow the Roadmap for Causal Inference. Epidemiology, Volume 34, Number 5. DOI: 10.1097/EDE.0000000000001637
2. Johnson, A., Bulgarelli, L., Pollard, T., Horng, S., Celi, L. A., & Mark, R. (2023). MIMIC-IV (version 2.2). PhysioNet. <https://doi.org/10.13026/6mm1-ek67>.
3. Zheng, W. and van der Laan, M. (2010). Asymptotic Theory for Cross-Validated Targeted Maximum Likelihood Estimation. Working Paper 273, University of California, Berkeley, Berkeley, CA.




➤ Figure 1. Treatment-specific means stratified by JC status: 1 = chronic kidney or liver disease. (dashed line is null effect)

Results

- Of 17,504 eligible cases, 1,566 developed a pressure injury (8.9%).
- The serum albumin treatment-specific means showed a significant protective effect [Figure 1]
- Additionally, when considering albumin exposure quintiles, the effect estimate is monotonic, increasing the risk with decreasing albumin quintiles [Figure 2]

Conclusions

- Serum albumin likely plays a causal (protective) role in PrI formation, **although for a subset of patients with kidney or liver problems the benefit is attenuated.**
 - This diminished benefit is likely due to pathology in albumin synthesis in liver disease and loss of albumin through the urine in kidney disease, e.g., in proteinuria, a hallmark of kidney disease.
- **The roadmap for causal inference proved to be an effective causal framework for statistical learning to identify and apply an estimation strategy all while accounting for potential confounding mechanisms.**



➤ Figure 2. Dose-response curve: Expected means for counterfactual serum albumin quintiles (shaded area is 95% simultaneous confidence band). (dashed line is cohort average PrI rate)

